MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-13
DOI
10.1038/s41598-019-55170-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MALAT1 Promotes the Proliferation and Metastasis of Osteosarcoma Cells By Activating the Rac1/JNK Pathway Via Targeting MiR-509
- (2018) Yong Zhang et al. ONCOLOGY RESEARCH
- AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex
- (2016) Anna de Polo et al. Journal of Molecular Cell Biology
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma
- (2015) Yixin Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database
- (2015) Kyle R. Duchman et al. Cancer Epidemiology
- Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment
- (2015) Chao Zhang et al. CELL CYCLE
- Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells
- (2015) KYUNG-CHAN KIM et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Axl as a mediator of cellular growth and survival
- (2015) Haley Axelrod et al. Oncotarget
- Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
- (2014) C. Khanna et al. CLINICAL CANCER RESEARCH
- Recent advances in osteosarcoma
- (2014) Sander M Botter et al. CURRENT OPINION IN PHARMACOLOGY
- Inhibition of Cell Proliferation and Migration by miR-509-3p That Targets CDK2, Rac1, and PIK3C2A
- (2014) Sena Yoon et al. MOLECULES AND CELLS
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression
- (2013) L H Chan et al. ONCOGENE
- The Adolescent and Young Adult with Cancer: State of the Art - Bone Tumors
- (2013) Nino Rainusso et al. Current Oncology Reports
- ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer
- (2012) J. Hong et al. CANCER RESEARCH
- ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
- (2012) Young-Ho Ahn et al. JOURNAL OF CLINICAL INVESTIGATION
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
- (2012) A N Rettew et al. Oncogenesis
- MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression
- (2011) Mitsuhiko Osaki et al. MOLECULAR THERAPY
- Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1
- (2010) Hoon Kim et al. BMC Medical Genomics
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started